Company
10 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
AUG 17, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for fenofibrate labeling change; describes a regulatory action, not clinical efficacy or comparative trial data.
JUL 29, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of mycophenolate mofetil hydrochloride injectable formulation under REMS requirements; regulatory action without clinical trial outcome data.
FDA approval of a generic hydrocortisone topical lotion formulation; this is a regulatory action, not a clinical efficacy study.
JUL 16, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for azathioprine labeling change; regulatory action without clinical trial data or efficacy claims.
JUL 1, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for verapamil hydrochloride labeling; this is a regulatory action record without clinical trial data and does not establish efficacy or comparative benefit.
JUN 18, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for morphine sulfate extended-release tablets; regulatory action record without clinical trial data.
JUN 5, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for abiraterone acetate labeling update; regulatory action does not establish clinical efficacy or comparative benefit.
MAY 15, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
This is an FDA supplemental approval action for lorazepam labeling; it documents a regulatory decision, not clinical evidence of efficacy or safety.